Last updated: February 24, 2026
What is NDC 00178-0600?
NDC 00178-0600 refers to Bupropion Hydrochloride Extended-Release (SR and XL) formulations, marketed primarily under the brand names Wellbutrin SR and Wellbutrin XL. Bupropion is an antidepressant and smoking cessation aid approved by the FDA. Its indications include depression, seasonal affective disorder, and nicotine dependence.
Market Dynamics
Market Size and Penetration
The global antidepressant market was valued at roughly USD 17 billion in 2022, with Bupropion accounting for approximately 12% of the US market.
US prescriptions for Bupropion reached about 10 million annually as of 2022, driven by its dual-use as an antidepressant and smoking cessation medication.
Competitive Landscape
Key competitors include:
- Generic Bupropion: Dominates the market due to lower prices.
- Brand-Name Drugs: Wellbutrin SR and XL account for a significant share but face generic erosion since patent expiration in 2017.
- Emerging Therapies: Newer antidepressants and combination therapies, including novel mechanisms of action, pose potential competition.
Patent and Exclusivity Status
No active patents specifically protect NDC 00178-0600 formulations. The primary patents for Wellbutrin expired between 2017 and 2019, leading to increased generic availability.
Regulatory Environment
The FDA approved generic versions starting from 2018. The generic market has saturated with multiple manufacturers offering both immediate-release and sustained-release formulations.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per unit (30-day supply) |
% Change YoY |
| 2018 |
USD 180 |
- |
| 2019 |
USD 160 |
-11.1% |
| 2020 |
USD 150 |
-6.25% |
| 2021 |
USD 135 |
-10.0% |
| 2022 |
USD 125 |
-7.41% |
Post-patent expiration, prices declined sharply due to increased generic competition. The current average retail price for a 30-day supply ranges between USD 125 and USD 150, depending on supplier and formulation.
Price Projection (Next 3 Years)
| Year |
Predicted AWP per 30-Day Supply |
Drivers |
| 2023 |
USD 118 |
Continued generic competition, price erosion |
| 2024 |
USD 112 |
Market saturation, no new formulations released |
| 2025 |
USD 105 |
Price stabilization with minor reductions |
Forecast assumes no significant regulatory changes or patent litigations that could alter generic market entry or pricing power.
Market Share and Revenue Projections
Assuming stable prescription volumes at current levels:
| Year |
Estimated Prescriptions (millions) |
Revenue Estimate (USD billions) |
| 2022 |
10 |
USD 1.25 billion |
| 2023 |
10 |
USD 1.18 billion |
| 2024 |
10 |
USD 1.12 billion |
| 2025 |
10 |
USD 1.05 billion |
Adjusted for price decreases, revenue from NDC 00178-0600 formulations is expected to decline modestly, barring shifts in prescribing patterns.
Key Factors Impacting Future Pricing and Market Size
- Generic Competition: Dominates the market, constraining prices.
- New Formulations: Limited pipeline; no recent patent protections.
- Regulatory Actions: Potential for FDA approval of biosimilars or new indications.
- Market Demand: Steady due to consistent prescription rates for mental health and smoking cessation.
Conclusion
The NDC 00178-0600 segment faces sustained price pressure due to established generic competition. Market size remains stable with approximately USD 1.2 billion in annual revenue based on current prescription volumes. Price projections suggest further declines over the next three years, stabilizing around USD 105-110 for a 30-day supply.
Key Takeaways
- No current patent protections; legacy branded formulations have largely transitioned to generics.
- Market volume is stable but prices have declined significantly since patent expiry.
- Price normalization is projected for 2024-2025 with small reductions.
- Revenue is expected to decrease proportionally, remaining in the USD 1 billion range annually.
- Future growth hinges on new formulations, indications, or regulatory changes.
FAQs
1. What are the main competitive threats to NDC 00178-0600?
Generic formulations from multiple manufacturers dominate the market, exerting downward pricing pressure.
2. How have patent expirations affected market prices?
Patent expirations in 2017-2019 led to aggressive price reductions due to multiple generic entrants.
3. Are there any new formulations or patents expected for this drug?
No significant new formulations or patents are currently under development or pending approval.
4. What impact could regulatory changes have on prices?
New indications, approvals for biosimilars or biosimilar-like formulations, could influence market dynamics and pricing.
5. Is market saturation likely to change prescription volumes?
Prescription volumes are stable; no significant growth expected unless new therapeutic uses are approved.
References
[1] IQVIA. (2022). Prescription Data for Bupropion.
[2] U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
[3] MarketWatch. (2022). Antidepressant Market Size and Trends.
[4] EuroMonitor. (2022). Global Prescription Pharma Pricing Trends.
